Allena Pharmaceuticals, Inc. (ALNA) News
Filter ALNA News Items
ALNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALNA News Highlights
- ALNA's 30 day story count now stands at 2.
- Over the past 23 days, the trend for ALNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest ALNA News From Around the Web
Below are the latest news stories about ALLENA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNA as an investment opportunity.
Allena Pharma Needs To Raise Capital To Continue As A Going ConcernAllena Pharmaceuticals Inc (NASDAQ: ALNA) says it lacks the financial resources to conduct studies for ALLN-346 for hyperuricemia and gout in the setting of advanced chronic kidney disease. The company continues to evaluate the data from cohorts A and B of Study 202 and the long-term viability of the ALLN-346 clinical program. In light of the clinical data observed to date, in particular the data from Study 201, which demonstrated a potential GI-based mechanism of action, it is possible that the |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning! |
Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney DiseaseNEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disea |
Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock SplitNEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to ef |
Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock SplitNEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of in |
Allena Pharmaceuticals (ALNA) Receives a Hold from H.C. WainwrightIn a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Allena Pharmaceuticals (ALNA – Research Report). The company's shares closed last Tuesday at $0.11, close to its 52-week low of $0.07. According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -30.4% and a 18.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Allena Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $0.50. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $1. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning! |
ALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%Allena Pharmaceuticals (ALNA) stock is rocketing higher on heavy trading Thursday despite a lack of news from the company. |
Why Is Lucid Motors (LCID) Stock Up Today?Lucid Motors (LCID) stock is on the move Thursday with heavy trading despite a lack of news from the electric vehicle (EV) company. |
Allena Pharmaceuticals Announces $2.8 Million Registered Direct OfferingNEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into a securities purchase agreement with an investor for the issuance and sale of an aggregate of 1,436.0688 shares of its Series D Convertible Preferred Stock, and 1,436.068 |